(Total Views: 481)
Posted On: 07/31/2025 12:46:45 PM
Post# of 155721
IL-6 cytokine -slow day
"...Unlike currently approved autologous CD19 CAR T cell products, which require patient
specific manufacturing and face logistical limitations, azer-cel is designed as an
allogeneic (donor-derived), off-the-shelf therapy that could significantly improve access
and treatment timelines. Patients in this study are treated with a combination of
lymphodepletion, azer-cel, and interleukin-2 (IL-2), a cytokine known to enhance CAR T cell function and longevity. "
https://mcusercontent.com/e38c43331936a9627ac...Report.pdf
"...Unlike currently approved autologous CD19 CAR T cell products, which require patient
specific manufacturing and face logistical limitations, azer-cel is designed as an
allogeneic (donor-derived), off-the-shelf therapy that could significantly improve access
and treatment timelines. Patients in this study are treated with a combination of
lymphodepletion, azer-cel, and interleukin-2 (IL-2), a cytokine known to enhance CAR T cell function and longevity. "
https://mcusercontent.com/e38c43331936a9627ac...Report.pdf
(0)
(0)
